Merck, Eisai to discontinue late-stage study for skin cancer
- Stock Market Stocks to buy Stocks to sell
admin
- 0
- 1 minute read
Merck & Co Inc and Eisai Co Ltd said on Friday they were discontinuing a late-stage study of Keytruda plus Lenvima for treatment of adults with unresectable or metastatic melanoma, as the trial did not show improvement in overall survival.
:max_bytes(150000):strip_icc():format(jpeg)/Primary-Image-how-to-trade-0dte-options-7481013-c9af6887219942dc9c8c9374963b51ec.jpg "How to Trade 0DTE Options")
